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The human kinesin Eg5 is responsible for bipolar spindle
formation during early mitosis. Inhibition of Eg5 triggers the
formation of monoastral spindles, leading to mitotic arrest that
eventually causes apoptosis. There is increasing evidence that
Eg5 constitutes a potential drug target for the development of
cancer chemotherapeutics. The most advanced Eg5-targeting
agent is ispinesib, which exhibits potent antitumour activity
and is currently in multiple phase II clinical trials. In this study,
the crystal structure of the Eg5 motor domain in complex with
ispinesib, supported by kinetic and thermodynamic binding
data, is reported. Ispinesib occupies the same induced-fit
pocket in Eg5 as other allosteric inhibitors, making extensive
hydrophobic interactions with the protein. The data for the
Eg5–ADP–ispinesib complex suffered from pseudo-mero-
hedral twinning and revealed translational noncrystallo-
graphic symmetry, leading to challenges in data processing,
space-group assignment and structure solution as well as in
refinement. These complications may explain the lack of
available structural information for this important agent and
its analogues. The present structure represents the best
interpretation of these data based on extensive data-reduction,
structure-solution and refinement trials.
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1. Introduction
Proteins involved in mitosis are attractive potential targets for
cancer therapy, as their inhibition may allow the specific
targetting of proliferating cells (Bergnes et al., 2005; Harrison
et al., 2009). Indeed, there are a number of antimitotic drugs in
clinical use, all of which target microtubule (MT) dynamics.
Unfortunately, however, these drugs show significant side
effects, as MTs are involved in a wide variety of cellular
processes aside from mitosis.
Kinesin motor proteins move along MTs in an ATP-
dependent manner. While they are conventionally thought to
function in cellular cargo transport, a number of kinesins have
been found to act during mitosis (Wordeman, 2010), making
them potential targets for antimitotic drugs (Good et al.,
2011). In fact, some of the mitotic kinesins appear to function
exclusively during mitosis and as such they may deliver on the
promise of an improved side-effect profile in anticancer
therapy through inhibition of mitotic proteins.
Human Eg5 (KSP, kinesin spindle protein, KIF11), a
member of the kinesin-5 family (Miki et al., 2003), is a well
characterized mitotic kinesin that is required to establish a
bipolar mitotic spindle. Eg5 forms homotetramers that can
attach to neighbouring antiparallel spindle MTs and slide
them against each other, thus separating the duplicated
centrosomes (Kapitein et al., 2005).
Loss of Eg5 function owing to RNA interference or small-
molecule inhibitors results in the formation of monoastral
spindles, cell-cycle arrest and apoptosis (Blangy et al., 1995;
Weil et al., 2002; Mayer et al., 1999). A number of small-
molecule inhibitors of Eg5 have been identified, including
MK-0731, pyrrolotriazin-4-one-based inhibitors and the
quinazolin-4-one-based ispinesib (Cox & Garbaccio, 2010;
Lad et al., 2008; Kim et al., 2006), all of which are allosteric
inhibitors that bind to the unique L5 loop region of the
catalytic domain. Ispinesib (also named SB-715992 or
CK0238273) is a potent and selective inhibitor of Eg5 that is
currently in multiple phase II clinical trials (Burris et al., 2011;
Souid et al., 2010) and is one of the most advanced drug
candidates. The importance of the quinazolin-4-one scaffold
targeting Eg5 is further underlined by the fact that three
structurally related compounds are in various stages of clinical
development: SB-743921, a second-generation ispinesib
analogue (Holen et al., 2011), AZD4877 (Esaki et al., 2011)
and Arq621 (Chen et al., 2011). A greater understanding of the
molecular details of the protein–inhibitor interactions of this
class of compounds is therefore crucial.
Although an Eg5–ispinesib complex has been reported
previously (Zhang et al., 2008), no coordinates or experi-
mental data were made available, which hampers detailed
analysis of this important enzyme–inhibitor interaction and
the use of the complex for further structure-guided design.
Here, we report the 2.6 A˚ resolution structure of the ternary
complex of the Eg5 motor domain in complex with Mg2+ADP
and ispinesib. The structure provides a detailed overview of
the interaction between ispinesib and the Eg5 motor domain
and a rationale for further drug development.
2. Methods
2.1. Cloning, expression and purification of Eg5
The motor domain of human Eg5 (residues 1–368) was
cloned, expressed and purified as described previously (Kaan
et al., 2010).
2.2. Steady-state ATPase-activity assay
Steady-state basal and MT-stimulated ATPase rates were
measured using the pyruvate kinase/lactate dehydrogenase
linked assay (Hackney & Jiang, 2001). The amounts of Eg5
were optimized to 80–100 nM for basal and 5 nM for MT-
stimulated activity assays. The IC50 values for the inhibition of
the basal and MT-stimulated ATPase activities of Eg5 were
measured for ispinesib up to 3.0 and 1.5 mM. The ATP
concentration was fixed at 1 mM and MTs were used at 2 mM
where applicable. Data were analysed using Kaleidagraph
v.4.0 (Synergy Software). ATPase measurements were
performed at 298 K using a 96-well Sunrise photometer
(Tecan, Mannesdorf, Switzerland). MTs were prepared from
lyophilized tubulin (tebu-bio catalogue No. 027T240-B) as
described previously (Kozielski et al., 2007).
2.3. Isothermal titration microcalorimetry (ITC)
ITC was performed as described previously by Sheth et al.
(2009) with minor modifications. Purified Eg5 was subjected
to gel-filtration chromatography in buffer A (20 mM PIPES
pH 6.8, 300 mM NaCl, 2 mM -mercaptoethanol) to remove
excess ATP and was then dialyzed overnight against buffer A
supplemented with 0.5 mM ADP and 5 mM MgCl2. The
protein was diluted to a final concentration of 20 mM with
dialysis buffer. The protein concentration was then verified by
absorption measurements at 280 nm employing an experi-
mental extinction coefficient determined using Eg5 denatured
in 6.7M guanidine hydrochloride with 20 mM phosphate pH
7.0 and including the absorption of ADP. Finally, 1% DMSO
was added to the protein solution. The inhibitor was prepared
in 100% DMSO and then diluted in dialysis buffer to a final
concentration of 250 mM ispinesib with 1% DMSO. All solu-
tions were centrifuged for 5–10 min at room temperature prior
to loading of the samples into the ITC cell. ITC experiments
were performed with a Microcal VP-ITC titration calorimeter
(Microcal Inc., North Hampton, Massachusetts, USA). All
titrations were carried out at 298 K with a stirring speed of
350 rev min1. A total of 26 injections were performed per
titration; the first injection of 5 ml was followed by 25 injec-
tions of 10 ml with a gap of 240 s between them. The heat of
dilution was subtracted prior to data analysis. The thermo-
dynamic parameters n (stoichiometry), Ka (association
constant) and H (enthalpy change) were obtained through
fitting of the experimental data using the single-site binding
model of the Origin software package (v.7.0); the free energy
of binding (G) and entropy change (S) were then calcu-
lated from the fitted values. For each experiment, at least two
independent titrations were performed which were analysed
independently. The resulting thermodynamic values were then
averaged.
2.4. Crystallization of the Eg5–ispinesib complex
Purified Eg5 at 10 mg ml1 was mixed with 1 mMMg2+ATP
and then incubated with ispinesib at a final concentration of
1 mM for 2 h at 277 K; the sample was then centrifuged at
14 000g for 5 min at 277 K to pellet undissolved inhibitor.
Initial crystals of the complex were obtained at 277 K by
vapour diffusion in sitting or hanging drops consisting of
200 nl protein–inhibitor complex and 200 nl reservoir solution
equilibrated against a reservoir consisting of 0.1M Tris pH 8.5,
0.02M MgCl2, 20%(w/v) polyethylene glycol (PEG) 8000.
Crystals were subsequently grown using identical conditions
in 24-well plates (Linbro, Hampton Research) using drops
consisting of 1 ml protein solution and 1 ml reservoir solution
and were improved by streak-seeding to generate crystals with
a rectangular plate morphology that were suitable for data
collection. Prior to data collection, crystals were immersed in
cryoprotectant solution [0.12M Tris pH 8.5, 0.024M MgCl2,
24%(w/v) PEG 8000, 15% glycerol] and flash-cooled in liquid
nitrogen.
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2.5. Data collection, structure determination, refinement and
model quality
Diffraction data were collected at 100 K on beamline I02
at Diamond Light Source. Data were processed and scaled to
2.6 A˚ resolution using XDS/XSCALE (Kabsch, 2010), then
truncated and further processed with the CCP4 suite of
programs (Winn et al., 2011). The structure of the Eg5–ispi-
nesib complex was solved in space group P21 by molecular
replacement with MOLREP using the Eg5 tetramer of PDB
entry 2gm1 as the search model (Kim et al., 2006). Twinning
analysis was carried out with phenix.xtriage from the PHENIX
suite (Adams et al., 2002). Iterative improvement of this
structure then proceeded through cycles of model building
with Coot (Emsley & Cowtan, 2004) and refinement using
PHENIX or REFMAC5 (Murshudov et al., 2011), resulting in
a final model with an Rfree of 25.3% and overall reasonable
geometry. Coordinates and dictionaries for ispinesib were
obtained from the Dundee PRODRG server (Schu¨ttelkopf &
van Aalten, 2004). Crystallographic statistics are given in
Table 1. Coordinates and structure factors have been depos-
ited in the Worldwide Protein Data Bank (PDB entry 4ap0).
In the Ramachandran plot, 98.1% of the residues are in
preferred regions, 1.9% of the residues are in allowed regions
and there are no outliers (as calculated byMolProbity; Chen et
al., 2010). Plots of per-residue real-space correlation coeffi-
cients (calculated with SFCHECK; Vaguine et al., 1999) and B
factors are shown in Fig. 1.
3. Results and discussion
3.1. Biochemical and biophysical investigation of ispinesib
binding
While it has been well established that ispinesib inhibits the
MT-stimulated Eg5 activity with low nanomolar affinity
(IC50 = 5.0  0.5 nM; Sheth et al., 2009), we were interested in
determining whether the same holds true in the absence of
MTs in order to obtain an indication of whether Eg5–ispinesib
research papers
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Table 1
Data-collection and structure-refinement statistics for the Eg5–ispinesib
complex.
Values in parentheses pertain to the highest resolution shell of 0.15 A˚.
Ramachandran plot statistics were obtained with MolProbity (Chen et al.,
2010).
Unit-cell parameters (A˚, ) a = 64.7, b = 112.6, c = 106.9,
 = 90.0
Space group P21
Molecules per asymmetric unit 4
Resolution range (A˚) 30.0–2.6
Total reflections 134457
Unique reflections 45511
Completeness (%) 95.7 (91.0)
Multiplicity 3.0 (2.7)
Rmerge (%) 6.9 (62.2)
hI/(I)i 13.3 (2.0)
Rwork/Rfree (%) 20.4/25.3
Wilson B (A˚2) 59.9
Average B (A˚2)
Overall 57.7
Protein 58.2
Solvent 48.1
ADP 33.8
Ispinesib 44.9
R.m.s.d. bond lengths (A˚) 0.016
R.m.s.d. bond angles () 1.47
Ramachandran plot statistics (%)
Favoured 98.1
Allowed 1.9
Outliers 0
Figure 1
Plots of per-residue average B factors (a) and real-space correlation coefficients (b) for chains A (blue), B (red), C (black) andD (green). The real-space
correlation coefficient (RSCC) was calculated with SFCHECK (Vaguine et al., 1999) using a A-weighted 2Fo  Fc map.
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Figure 2
Characterization of the inhibition of Eg5 by ispinesib. Inhibition of the (a) basal and (b) MT-stimulated ATPase activity of Eg5. (c) Raw (top) and
integrated (bottom) ITC data demonstrating saturable exothermic evolution of heat upon sequential additions of ispinesib to Eg5. 1 cal = 4.184 J.
cocrystallization (which precludes the presence of MTs) would
be likely to succeed in our hands (Table 2, Figs. 2a and 2b).
While the IC50 estimate obtained for MT-stimulated ATPase
activity (IC50,MT = 3.0 0.4 nM) agrees well with the literature
data, in the absence of MTs the IC50 of ispinesib increases
by one order of magnitude to 32.8  0.5 nM. Given the
different protein concentrations used in the assays, it is not
uncommon for tight-binding inhibitors to appear less potent
against the basal compared with the MT-stimulated ATPase
activity of kinesins. However, this drop in affinity should not,
and indeed does not, impede complex crystallization. Sheth et
al. (2009) also performed microcalorimetric binding studies on
the Eg5–ispinesib system (now in the absence of MTs), which
yielded dissociation constants of less than 10 nM. To further
investigate this discrepancy, we repeated the ITC experiment
on the binding of ispinesib to Eg5 (Table 3, Fig. 2c). Our
calorimetric measurements show that even in the absence of
MTs ispinesib is a tight-binding Eg5 ligand (Kd < 10 nM),
which is in agreement with the data of Sheth et al. (2009).
3.2. Overall structure
The structure of the Eg5–ispinesib complex was solved at
2.6 A˚ resolution and refined to an Rfree of 25.3% with four
protein molecules in the asymmetric unit. Depending on the
molecule, the N-terminal 15–17 residues as well as the
C-terminal 2–9 residues of Eg51–368 are disordered, as are a
number of loops; in particular, loops L10 and L11 (Fig. 3)
are absent from all four molecules. Aside from this, the four
independent complexes in the asymmetric unit are mostly
Table 2
Inhibition of Eg5 ATPase activity by ispinesib.
Basal MT-stimulated
IC50 (nM) 32.8  0.5 3.0  0.4
similar, with pairwise superpositions giving r.m.s. deviations of
around 0.6 A˚ for 300 C atoms. For the sake of clarity, the
further discussion will thus focus only on chain B unless stated
otherwise.
The present structure conforms to the canonical kinesin
motor domain fold with an eight-stranded -sheet sandwiched
between three major -helices on either side (Figs. 3a and 3b).
It shows one molecule of Mg2+ADP bound in the nucleotide-
binding pocket with the magnesium coordinated by the
-phosphate, the side-chain hydroxyl of Thr112 and three
water molecules, resulting in an octahedral geometry with one
disordered ligand (presumably bulk solvent). Ispinesib occu-
pies the inhibitor-binding pocket formed by helix 2, loop L5
and helix 3 (Fig. 3a).
Comparison with apo Eg5 (PDB entry 1ii6; Turner et al.,
2001) shows that the region around the inhibitor-binding
pocket undergoes major conformational changes on ispinesib
binding. Additional changes extend towards the other end of
the motor domain, bringing about larger conformational
changes in the switch II cluster (helix 4, loop L12 and helix
5) and the neck-linker region (Yan et al., 2004). All four
molecules in the asymmetric unit depict the final ispinesib-
bound state. Helix 4 rotates and moves by around 7 A˚ in the
inhibitor-bound state compared with the native structure. The
anticlockwise rotation and shift of helix 4 rearranges the
switch II cluster and opens up space enabling the neck-linker
to dock to the motor domain (Figs. 3b and 3c). This shows that
ispinesib brings about structural changes in the Eg5 catalytic
domain, in agreement with published biochemical data (Lad et
al., 2008).
3.3. Ispinesib binding to Eg5 and comparison with other
allosteric inhibitors
Ispinesib is buried in the allosteric site and displays
numerous interactions with residues of the inhibitor-binding
pocket (Fig. 4a; Zhang et al., 2008). At the resolution obtained
for this structure, we did not observe any ordered water
molecules in close proximity to the inhibitor. The benzyl
moiety of the ligand is buried deeply in the hydrophobic part
of the pocket, where it stacks with the Pro137 ring and makes
an edge-to-face interaction with the side chain of Trp127, as
well as hydrophobic interactions with the side chains of Tyr211
and Leu214. In addition, the benzyl group also forms an
intramolecular edge-to-face stacking interaction with the
p-toluyl moiety of the inhibitor, which in turn stacks exten-
sively with the mostly flat protein backbone of Glu118/Arg119
and also interacts with parts of the side chains of Arg119,
Trp127 and Asp130. The isopropyl group of ispinesib is only
partly buried between the side chains of Tyr211 and Leu214
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Table 3
Thermodynamic data for the binding of ispinesib to Eg5–ADP.
Owing to the tight binding of ispinesib, the measured apparent Kd can only be
treated as an upper limit. 1 cal = 4.186 J.
n Kd
app (nM) H (kcal mol1) TSapp (kcal mol1)
1.270  0.003 10 9.08  0.04 2.81  0.23
Figure 3
Overall structure of the ADP–Eg5–ispinesib ternary complex (chain B). (a) Front view of the Eg5 motor domain in complex with Mg2+ (red), ADP
(blue) and ispinesib (magenta); red dotted lines indicate the locations of the disordered loops L10 and L11, and selected secondary-structure elements
and loops are labelled. (b) Back view of the Eg5 motor domain with 4 of the switch II cluster, the neck-linker region as well as the preceding 6 helix
highlighted in magenta. (c) Detailed view of helices 4 and 6 as well as the neck-linker region of the Eg5–ispinesib complex (magenta) superimposed on
the apo Eg5 structure (blue; PDB entry 1ii6; Turner et al., 2001).
as well as the backbone of the latter residue and Glu215.
The chlorine substituent of the 7-chloro-3,4-dihydro-4-oxo-
3-(phenylmethyl)-2-quinazolinyl moiety sits in another mostly
hydrophobic pocket formed by the backbone of Gly217 and
the side chains of Leu160, Leu171 and Arg221. In three of the
four chains (B/C/D) the primary amine of ispinesib is oriented
towards the ADP-binding site, and while it is mostly solvent-
exposed the amine can interact favourably with the anionic
Glu116 side chain. In chain A, in contrast, the aminopropyl
moiety is disordered. Taken together, the intrinsic flexibility of
the aminopropyl group, together with the observed confor-
mational variability and its mostly solvent-exposed position,
suggests that this functional group is less important for the
binding of ispinesib to Eg5 than in other Eg5-targeting
compounds which also contain this primary amine. This is
further underlined by STLC and related analogues: in this case
the primary amine is absolutely essential for Eg5 inhibition
(Debonis et al., 2008) and an analogue with a tertiary amine
completely abolishes inhibition, whereas a tertiary amine in
ispinesib is still capable of inhibiting Eg5 in the low-nanomolar
range (Sakowicz et al., 2004). It is remarkable that aside from
the salt bridge between this primary amine and the Glu116
carboxylate, ispinesib makes exclusively hydrophobic inter-
actions with the protein. In this context, it is particularly
noteworthy that the carbonyl oxygen group of the quinazolin-
4-one ring system is buried in a hydrophobic pocket, which
frustrates its hydrogen-bonding potential. While several
potential weak C—H  O hydrogen bonds are likely to at
least partially compensate for this, the replacement of this
group by a similarly sized hydrophobic group should provide
improvements to Eg5 binding, although these modifications
will have to be carefully balanced with its drug-like properties.
Although the unavailability of coordinates/structure factors
precludes a detailed analysis, we felt it would be informative
to compare our structure with the previously published Eg5–
ispinesib complex (Zhang et al., 2008). Overall, the two models
research papers
1316 Talapatra et al.  Eg5–ADP–ispinesib complex Acta Cryst. (2012). D68, 1311–1319
Figure 4
Interactions of ispinesib with the Eg5 inhibitor-binding region and comparison with other inhibitors of Eg5. (a) Chemical structure of ispinesib (left);
stereoview of ispinesib (purple sticks) bound to the allosteric site of Eg5. Side chains and/or backbone atoms of interacting protein residues are shown as
grey sticks and labelled; the protein surface is displayed semitransparently. Unbiased (i.e. calculated prior to including the ligand in the model)
A-weighted Fo  Fc electron density for the ligand contoured at 2.5 is shown in slate. (b) Chemical structure (left) and comparison of the Eg5 binding
mode (right) of ‘compound 24’ (orange). (c) Chemical structure (left) and comparison of the Eg5 binding mode (right) of MK-0731 (orange).
adopt a similar ‘final state’ conformation, although the
previous structure exhibits a number of features that are
unusual among published Eg5 structures and are not repli-
cated by our model. Specifically, the helix between 1 and 1a,
as well as parts of the central -sheet around 6/7, are shifted
significantly with respect to the present complex structure.
Additionally, loop 11 is ordered in the former structure, while
in essentially all other Eg5 complex structures it is disordered.
Zhang and coworkers suggest that these differences from
the ‘canonical’ Eg5 conformation are a consequence of crystal
contacts, which is plausible given their unique unit-cell para-
meters and is furthermore compatible with these features
being absent from the present structure. Based on the
discussion and figures provided by Zhang and coworkers, the
conformation and binding mode of ispinesib appears to be
virtually identical in the two structures, down to the orienta-
tion of the flexible aminopropyl group. While the isopropyl
moiety of the ligand was apparently and unexpectedly
modelled as a flat group in the previous structure, this has little
effect on the observed ligand–protein interactions.
To further investigate the binding mode of ispinesib, we
compared the structure of ispinesib-bound Eg5 with the
Eg5-complex structures of two other related inhibitors: the
pyrrolotriazin-4-one-based ‘compound 24’ (PDB entry 2gm1;
Kim et al., 2006) and MK-0731 (PDB entry 2cjo; Cox et al.,
2008) (Figs. 4b and 4c).
Aside from the differences in the core ring system,
‘compound 24’ is virtually identical to ispinesib and it is thus
not surprising that the two molecules adopt similar binding
modes, with the benzyl, p-toluyl and aminopropyl groups all
adopting consistent conformations and making equivalent
interactions with the protein (Fig. 4b). The cyclopropyl group
of compound 24 takes the place of the isopropyl group of
ispinesib and again makes equivalent interactions. The most
significant difference between these two compounds lies in the
different attachment of the chlorine substituent to the core
ring system, which is partly necessitated by the change from a
quinazolinone (ispinesib) to a pyrrolotriazinone (compound
24). While the chlorine of ispinesib makes its closest contacts
with the Leu160 side chain and the backbone of Gly217, the
chlorine of compound 24 points deeper into the binding
pocket (the angle between the two C—Cl bonds after super-
position is 104), where it interacts predominantly with the
side chains of Ile136 and Phe239. Given that the almost
perfect alignment of the two core ring systems after super-
position of the two complex structures on the protein
component (cf. Fig. 4b) supports a lack of excessive strain
owing to the presence of either chlorine, thus might suggest
that the Eg5 affinity of either compound could be improved by
introducing additional substitutions on the benzo and pyrrolo
ring, respectively. At the same time, compound 24 is almost
two orders of magnitude less potent as an Eg5 inhibitor
compared with ispinesib (Kim et al., 2006), which might mean
that it is compound 24 rather than ispinesib that would benefit
most from such reciprocal elaboration.
While at first glance the 3-phenyl-dihydropyrrole-based
MK-0731 shares few chemical features with ispinesib, a
superposition of the two Eg5 complexes reveals the presence
of several congruent structural elements (Fig. 4c). The
difluorophenyl ring of MK-0731 takes the place of the
quinazolinone system of ispinesib, with one fluorine
mimicking the chlorine substituent of ispinesib and the second
fluorine superimposing reasonably well with the quinazolone
oxo group, although owing to the smaller size of F compared
with Cl as well as the steric requirements of the rest of the
molecule MK-0731 inserts less deeply into the binding pocket
than does ispinesib. The unsubstituted phenyl ring of MK-0731
binds in the general area occupied by the chemically similar
benzyl and p-toluyl groups of ispinesib. The reduced bulk and
the positioning of this phenyl enable the side chain of Arg119
to close as a lid over this part of MK-0731, enabling favourable
stacking interactions that are not accessible to ispinesib. A
feature unique to MK-0731 is the hydroxymethyl group
attached to the central dihydropyrrole ring. Introduced to
increase polarity and thus reduce hERG binding (Cox et al.,
2008), this group can be considered as related in purpose to
the aminopropyl moiety of ispinesib, but its reduced intrinsic
flexibility combined with local steric hindrance makes the
hydroxymethyl group a potentially better choice that may
inspire similar modifications in future ispinesib derivatives,
although they will have to be monitored for possible phase II
metabolic liabilities. Another feature unique to MK-0731 is its
fluoromethylpiperidine ‘side chain’. While it does interact with
the protein, this moiety is mostly solvent-exposed and as such
enables modulation of the physicochemical properties and thus
the pharmacokinetics of the inhibitor. Despite the divergent
binding features, ispinesib and MK-0731 are remarkably
similar in their affinity for Eg5 (the IC50 of MK-0731 for MT-
stimulated Eg5 is 2 nM; Cox et al., 2008), again suggesting that
‘transplanting’ features may yield improved Eg5 ligands.
3.4. Twinning and pseudotranslational symmetry
Several data sets were collected from Eg5–ADP–ispinesib
complex crystals, most of which could not be processed with
any commonly used software. The present data could be
indexed, processed and scaled in both primitive orthorhombic
and C-centred monoclinic space groups. Structure solution
by molecular replacement in these space groups was possible,
yielding initially reasonable models, all of which subsequently
failed to refine either because the R values could not be
decreased or because model completion revealed unavoidable
clashes or otherwise impossible molecular arrangements.
Decreasing the lattice symmetry to primitive monoclinic
allowed the structure to be solved in space group P21 for all
three possible choices of crystallographic symmetry axis. Two
of the three cell choices allowed model improvement through
iterative refinement, while the third was yet again unrefinable.
Inspection of the symmetry relationships between protein
molecules in the P21-refined models revealed three orthogonal
twofold symmetry axes, two of which can individually function
as crystallographic symmetry elements, while the third has a
screw component of 0.38 and as such provides only
noncrystallographic symmetry. These findings explain the lack
research papers
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of refinement of the various orthorhombic models as well as
one of the three P21 axis choices, although it is somewhat
surprising that believable models could be obtained from
molecular replacement in these cases at all, as interpreting the
‘odd’ screw axis as a crystallographic 21 symmetry axis would
impose a coordinate shift of more than 13 A˚ on parts of the
model.
In addition, the P21 model(s) exhibits pure translational
(noncrystallographic) symmetry that almost, but not quite,
mimics a face-centring operation, explaining why scaling and
molecular replacement were successful in C2 but again did
not yield a refinable model. To add insult to injury, the Eg5–
ispinesib complex crystals appear to suffer from pseudo-
merohedral twinning, as suggested by the Britton plot
(Britton, 1972), H-test (Yeates, 1997) and RvR plot (Lebedev
et al., 2006), and supported by a significant drop in R/Rfree of
over 7% when switching from untwinned to twinned refine-
ment in PHENIX, with the twin law a twofold axis orthogonal
to the crystallographic symmetry axis and a twin fraction of
around 0.4.
Both translational noncrystallographic symmetry and
twinning complicate structure solution and even for the valid
cell choices similar refinable but non-equivalent models were
obtained from molecular replacement. The final structure
presented here was selected based on refinement statistics,
crystallographic packing and precedent for this cell choice and
packing in the PDB in entry 2gm1 (Kim et al., 2006), the
protein component of which was subsequently used as a search
model for molecular replacement.
4. Conclusion and biological significance
Eg5 shows significant potential as a drug target for cancer
chemotherapy and correspondingly has attracted widespread
attention, with numerous inhibitors in various phases of drug
development. All Eg5 inhibitors developed to date target the
globular motor domain, where they bind to one of two distinct
sites: ATP-competitive inhibitors bind either in or close to
the ATP-binding site (P-loop; Luo et al., 2007; Parrish et al.,
2007), whereas allosteric inhibitors bind to the L5 loop region.
The allosteric Eg5 inhibitors are attractive not only because
they avoid binding in competition with ATP/ADP, but more
importantly because binding to the particularly long L5 loop
of Eg5 provides these compounds with specificity over other
closely related kinesins, which generally possess a much
shorter L5 loop that cannot furnish a comparable binding
pocket. Ispinesib is a promising allosteric Eg5 inhibitor that is
currently in phase II clinical trials. It is thus surprising that
no structural data for the Eg5–ispinesib complex have been
available to date. The present structure of the ternary Eg5–
ADP–ispinesib complex seeks to remedy this. It shows that
the ligand makes extensive hydrophobic, but essentially no
hydrophilic, interactions with the allosteric binding pocket of
Eg5. Analysis of the binding mode, as well as a comparison
with other allosteric Eg5 inhibitors, suggests a number of ways
in which ispinesib could be modified while either retaining or
even improving its affinity for Eg5, an argument that is further
supported by the development of the second-generation
ispinesib-based analogue SB-743921 (Holen et al., 2011) and
the amount of additional data on development of ispinesib-
related compounds in the patent literature (Matsuno et al.,
2008). This information should prove invaluable for future
iterations of this inhibitor scaffold, be it to improve potency,
to alter the pharmacokinetics or to counter the ever-present
threat of resistance (Jackson, 2005).
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